T. Kusayama

发表

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist

T. Sugimoto, M. Saito, J. Tsukada, 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs.

Y. Arai, J. Tsukada, A. Tahara, 2002, Pharmacological research.

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.

K. Honda, J. Tsukada, W. Uchida, 1999, European journal of pharmacology.

Binding and Signal Transduction Characteristics of the Nonpeptide Vasopressin V1A Receptor-Selective Antagonist YM218 in Cultured Rat Mesangial Cells

K. Momose, M. Shibasaki, J. Tsukada, 2006, Pharmacology.

Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.

M. Shibasaki, J. Tsukada, W. Uchida, 2005, Vascular pharmacology.

Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.

M. Shibasaki, J. Tsukada, W. Uchida, 2005, Pharmacological research.

Effects of YM471, a nonpeptide AVP V1A and V2 receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2001, British journal of pharmacology.

Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.

A. Fujimori, Y. Satoh, M. Takanashi, 1997, European journal of pharmacology.

Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.

J. Tsukada, W. Uchida, A. Tanaka, 2002, European journal of pharmacology.

Pharmacological Profile of YM 087 , A Novel Potent Nonpeptide Vasopressin V 1 A and V 2 Receptor Antagonist , in Vitro and in Vivo

M. Takanashi, J. Tsukada, W. Uchida, 1997 .

Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2002, Journal of hypertension.

Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2000, British journal of pharmacology.

Alterations of Renal Vasopressin V1A and V2 Receptors in Spontaneously Hypertensive Rats

J. Tsukada, W. Uchida, A. Tanaka, 2003, Pharmacology.

N-Methylbenzanilide derivatives as a novel class of selective V(1A) receptor antagonists.

J. Tsukada, S. Tsukamoto, A. Kakefuda, 2002, Bioorganic & medicinal chemistry letters.

Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences

J. Tsukada, W. Uchida, A. Tanaka, 1999, Regulatory Peptides.

Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells

T. Sugimoto, M. Saito, J. Tsukada, 1998, British journal of pharmacology.

Characterization of vasopressin receptor in rat lung

J. Tsukada, W. Uchida, A. Tanaka, 1998, Neuropeptides.

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.

J. Tsukada, W. Uchida, A. Tanaka, 1998, Cardiovascular research.

Binding Characteristics of YM087, an AVP Receptor Antagonist, in Rhesus Monkey Liver and Kidney Membranes

J. Tsukada, W. Uchida, A. Tanaka, 1998, Peptides.

Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs.

A. Fujimori, Y. Satoh, M. Shibasaki, 1997, European journal of pharmacology.

Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells.

J. Tsukada, W. Uchida, A. Tanaka, 1999, European journal of pharmacology.

AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors

T. Sugimoto, M. Saito, J. Tsukada, 1999, Pflügers Archiv.

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells.

J. Tsukada, W. Uchida, A. Tanaka, 1997, Journal of cardiovascular pharmacology.

Flow dependence of nitric oxide-mediated pressure change in rat mesenteric beds with different tonus.

T. Nagao, J. Yamazaki, T. Kusayama, 1996, European journal of pharmacology.

Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.

M. Takanashi, J. Tsukada, W. Uchida, 1997, The Journal of pharmacology and experimental therapeutics.

Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells

J. Tsukada, W. Uchida, A. Tanaka, 2002, Peptides.

Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells.

M. Saito, J. Tsukada, W. Uchida, 1999, European journal of pharmacology.

Binding of a catechol derivative of denopamine (T-0509) and N-tert-butylnoradrenaline (colterol) to β1- and β2-adrenoceptors

T. Nagao, S. Adachi-Akahane, J. Oka, 1994 .

Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.

M. Orita, J. Tsukada, A. Kakefuda, 2006, Bioorganic & medicinal chemistry.

Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.

J. Tsukada, A. Tanaka, Y. Shimada, 2005, Chemical & pharmaceutical bulletin.